Company profile for ILIAS Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells. Our platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therap...
At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells. Our platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
40-20 Techno 6ro, Yuseong-gu, Daejeon 34014
Telephone
Telephone
042-863-4450
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
After $500M IPO, HK inno.N enters exosome drug delivery
After $500M IPO, HK inno.N enters exosome drug delivery

31 May 2022

// Nick Paul Taylor FIERCEPHARMA

https://www.fiercepharma.com/pharma/after-500m-ipo-hk-innon-enters-exosome-drug-delivery-ilias-pact

Nick Paul Taylor FIERCEPHARMA
31 May 2022

https://www.prnewswire.com/news-releases/ilias-biologics-inc-demonstrated-the-therapeutic-effect-of-anti-inflammatory-exosomes-for-ischemia-reperfusion-induced-acute-kidney-injury-301320801.html

PR NEWSWIRE
28 Jun 2021

https://en.prnasia.com/releases/global/ilias-biologics-announces-the-2nd-poc-study-showing-anti-inflammatory-effects-of-ilb202-on-preterm-birth-307428.shtml

PRNASIA
02 Feb 2021

https://en.prnasia.com/releases/global/ilias-biologics-announces-the-2nd-poc-study-showing-anti-inflammatory-effects-of-ilb202-on-preterm-birth-307428.shtml

PRNASIA
01 Feb 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty